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a  b  s  t  r  a  c  t
Imbalances  in the regulation  of  pro-inﬂammatory  cytokines  have  been  increasingly  correlated  with sev-
eral neurodevelopmental  disorders  and  their  role  in  neuronal  development  is  being  investigated.  To
assess the  possible  inﬂuence  of  cytokines  on the  onset  of  intellectual  disability  (ID), we  studied  the
polymorphisms  of thirteen  proinﬂammatory  cytokine  genes  in  81  patients  and 61 healthy  controls.
We  demonstrated  a signiﬁcant  association  of interleukin-6  (IL-6)  single-nucleotide  polymorphism  (SNP)eywords:
ntellectual disability
ytokine
olymorphism
L-6
L-1RA
(−174 G/C  and  nt565  G/A),  and  interleukin-1  receptor  antagonist  (IL-1RA)  (Mspa-I  11100)  SNP  with  ID.
Moreover,  the  IL-6  SNPs  is an  unfavorable  genetic  predisposition  for  females.  The evaluation  of circulat-
ing  levels  of IL-6  and  IL-1RA  showed  that  the  serum  concentrations  of  IL-6  were  signiﬁcantly  higher  in ID
patients  than in  controls.  These  data  suggest  that  functional  cytokine  gene  polymorphisms  may  inﬂuence
the  development  of ID.
©  2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Intellectual disability (ID), also called mental retardation, is
haracterized by signiﬁcantly impaired cognitive functions and
ncludes a component relating to mental functioning and relat-
ng to an individuals’ functional skill in their environment. People
ith intellectual disabilities can learn new skills, but more slowly
ompared with normal individuals. The World Health Organiza-
ion describes ID as a disorder characterized by the presence of
ncomplete or arrested mental development, mainly owing to the
eterioration of concrete functions at each stage of development
hat contribute to the overall level of intelligence, such as cog-
itive, language, motor and socialization functions. Many causal
actors related to ID have been identiﬁed and can be classiﬁed as
enetic, acquired (congenital and developmental), environmental
nd socio-cultural [1]. However, in 40% of cases the cause of ID is
nknown [2].
ID has an estimated prevalence of 1–3% in developed countries
nd represents the result of several pathological processes that act
n the central nervous system (CNS) [3]. Over the years, human
enetic studies have identiﬁed many candidate genes that cause
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ID but the mechanisms by which these genes regulate cognitive
function remain poorly understood [4]. Among others, molecules
from the immune system, such as cytokines, have been reported
as important and interactions between the immune system and
CNS have long been under investigation. In particular, the discov-
ery of multiple functions of cytokines in the CNS suggests that
they play a central role in complex CNS functions such as cognition
[5,6] and cytokine-mediated pathophysiological processes under-
ling cognitive impairments [7,8]. Besides the detrimental effects on
cognitive function, mainly linked to neuroinﬂammation and neu-
ropathological processes, cytokines have important physiological
roles in CNS functions such as learning, memory and cognition.
Constitutive expression of cytokines in the CNS is primarily from
astrocytes and microglia, although neuronal expression has been
observed [7,9]. Speciﬁcally, evidence shows that pro-inﬂammatory
cytokines interleukin-1 (IL-1), IL-6 and tumor necrosis factor (TNF)
are involved in the molecular and cellular mechanisms that medi-
ate complex cognitive processes [10,11] and play a key role in
synaptic plasticity, long-term potentiation (LTP), neurogenesis and
memory consolidation [12]. In the CNS, cognition, as a complex of
processes such as attention, executive function, learning and mem-
ory, consciousness and language, is collectively dependent upon
hippocampal-dependent synaptic plasticity. Synaptic plasticity is
regulated by speciﬁc LTP and long-term depression (LTD), which
respectively strengthen or weaken synaptic connectivity following
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
Patient clinical features.
Sex
Male, n [%] 49 [60.5]
Female, n [%] 32 [39.5]
Average age in years ± SD 14 ± 4.08
Intellectual disability grade
Mild, n [%] 58 [71.6]
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oModerate, n [%] 22 [27.2]
Severe or profound, n [%] 1 [1.20]
timulation, and is the underlying cellular/molecular mechanism
mportant for memory consolidation [13–15]. It was demonstrated
hat both the over-expression and absence of cytokines directly
nﬂuenced hippocampal-dependent forms of memory and synaptic
lasticity [10,16,17].
Moreover, it is now an accepted clinical idea that imbalances
n the immune system, perhaps caused by interactions of multiple
ytokines, cause or contribute to many neurodevelopmental dis-
rders [18,19]. Elevated levels of pro-inﬂammatory cytokines have
een associated with autism and schizophrenia, Down syndrome
nd epilepsy [20–22].
Cytokines production is under genetic control. Individual dif-
erences in levels of interleukins can be attributed to gene
olymorphisms within the coding, intron, or promoter regions.
ecently, the association between genetic variants of cytokines
L-1, IL-6 and cognitive function [23] in healthy elders of the gen-
ral population was reported [24–27]. Despite these ﬁndings, the
nvolvement of inﬂammatory cytokines in cognitive disorders is not
ell understood. Because inherited genetic variation may have a
ey role in brain impairment, genetic evidence provides an impor-
ant means of establishing the role of cytokines in cognitive and
elational disorders.
To investigate an association among genetic polymorphic vari-
tions, plasma levels of proinﬂammatory cytokines and ID we
xamined single nucleotide polymorphisms (SNPs) of thirteen
ytokine genes. Moreover, serum levels of signiﬁcantly associated
ytokines SNPs were evaluated. The results suggest that IL-6 and
L-1RA SNPs may  have a role in ID and peripheral blood IL-6 con-
entrations are also associated with ID.
. Materials and methods
.1. Study participants
The study comprised 142 subjects: 81 ID patients and 61 unaf-
ected controls, matched for age and sex. The group of patients,
nrolled at the Department of Neuropsychiatric Disorders of the
ivil Hospital of L’Aquila, Italy, included 49 males and 32 females
ged between 23 and 5 years. Table 1 shows the demographic and
iagnostic characteristics of our ID patients.
The control subjects underwent a routine medical checkup in
he outpatient clinic of the Department of Pediatrics of the Civil
ospital of L’Aquila. A detailed clinical examination was performed
n all cases and a diagnosis of intellectual disability was  made
ccording to the Child Development and Neuropsychiatric Clinics
f the S. Salvatore Hospital, L’Aquila, Italy.
All study subjects were Italians and resided in the same geo-
raphic area in Italy. The study was performed with the approval of
he ethics committee (Prot. n. 0102550 – 10/21/2011) and written
nformed consent was obtained from all the subjects..2. Cognitive measures
Based on age, the Wechsler Primary and Preschool Scale
f Intelligence (WPPSI-R) and Wechsler Intelligence Scale forters 162 (2014) 124–131 125
children (WISC-III) were used to study intellectual functioning in
verbal and performance cognitive domains and the child’s general
intellectual ability. Vineland Adaptive Behaviour Scales were used
to measure personal and social skills required for everyday living.
The Child Behavior CheckList (CBCL) was used to detect emotional
and behavioral problems in children and adolescents and the Con-
ners’ Continuous Performance Test (C-CPT), which measures and
evaluates a child’s attention span and ability to maintain focus on
a task, was  used to support the conclusions.
Exclusion criteria for ID patients were genetic conditions
(Down syndrome, fragile X syndrome, and phenylketonuria).
Environmental conditions that interfere with the growth and
development of the brain such as prenatal (severe maternal mal-
nutrition, alcohol and drug abuse), during birth (hypoxia, extreme
prematurity) and after birth (severe head injury, malnutrition
of the child, severe emotional neglect or abuse) factors were
included.
2.3. DNA extraction
Genomic DNA was extracted from whole blood according to
the manufacturer’s protocol (QIAamp DNA blood MiniKit, Qiagen,
Courtaboeuf, France) and kept at −20 ◦C until use. DNA concen-
tration and purity was determined using a spectrophotometer
(Beckman Instruments, Inc. Fullerton, CA. 92834-3100).
2.4. Cytokine gene polymorphisms
Cytokine gene polymorphisms were investigated in patients and
controls using the Pel-Freez Cytokine Genotyping Kit, a PCR-based
method designed to detect simultaneously polymorphisms of thir-
teen cytokine genes (IL1, IL1, IL1R, IL1RA, IL4Ra, IL12, IFN,  TGF,
TNF, IL2, IL4, IL6, and IL10) (Fig. 1). Each tray contained forty-eight
formulations of speciﬁc lyophilized primer sets used to amplify
genomic DNA. Brieﬂy, PCR reactions were performed using a mix-
ture composed of PCR Buffer, water and Taq DNA Polymerase. A
volume of 50 L of DNA sample (75–125 ng/L) was  added to the
buffer mixture and 10 L of the reaction mixture was dispensed
into each well. The PCR products were then electrophoresed by
1.5% agarose gel containing 0.5 mg/ml  ethidium bromide and doc-
umented by photography. The genotype speciﬁcity was  determined
by the presence or absence of a speciﬁc PCR product of known
size.
2.5. Cytokine measurements
Serum samples from patients and healthy controls were sep-
arated from venous blood and stored at −80 ◦C until cytokine
analysis. The determination of cytokine levels was performed by
enzyme-linked immunosorbent assay (ELISA) using commercially
available kits (Human IL-6 ELISA Kit EH2IL6, Thermo scientiﬁc, and
Human IL-1RA ELISA Kit EK0782, Boster Biological Technology),
performed in accordance with the manufacturer’s protocol. The
sensitivity of the assays was <1 pg/ml for IL-6 and <2 pg/ml for IL-
1RA. Samples were run in triplicate and the mean value was used
for further statistical analysis.
3. Statistical analysis
Pearson’s chi-square test and Fisher’s exact test were used to
evaluate genotype and allele frequencies of all cytokines in both
ID patients and controls and the odds ratios (OR) and 95% con-
ﬁdence intervals (CIs) were calculated to assess the relative risk
conferred by a particular allele and genotype. Categorical variables
were compared by 2 test. Statistical signiﬁcance was assumed
when p < 0.05. To compare the mean values of cytokines, the
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Oig. 1. Scan of a representative cytokine genotyping worksheet. Below the table, a
X-174  HeIII digest molecular weight marker.
ann–Whitney U-test was used. Statistical analysis was  performed
sing IBM SPSS Statistics 16.0 software (SPSS/IBM, Chicago, IL,
SA).
. Results.1. Cytokine gene polymorphisms
The cytokine polymorphisms analyzed are shown in Fig. 2.
ur results demonstrated a statistically signiﬁcant associationge of a representative gel electrophoretic band patterns is inserted. MW indicates
between polymorphisms of IL-6 and IL-1RA and ID as shown in
Fig. 3. The presence of an IL-6 (−174) G/C genotype detected in
42.1% of patients and in 22.2% of controls indicated an increased
risk of developing ID (p < 0.05; OR: 2.60; 95% CI: from 1.188 to
5.716) whereas the IL-6 (−174) C/C (1.3% patients vs 16.3% con-
trols, p < 0.005; OR: 0.07; 95% CI: from 0.008 to 0.556) and IL-6
(nt565) A/A (1.3% patients vs 14.5% controls, p < 0.005; OR: 0.089;
95% CI: from 0.009 to 0.646) genotypes were protective. More-
over, a positive association of IL-1RA Mspa-I 11100 T/T genotype
(p < 0.05; OR 2.33; 95% CI: from 1.117 to 4.625) and a negative
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eig. 2. Frequency distributions of IL-6 174 (top) and nt565 (bottom) genotypes in
hi-square test and Fisher’s exact test were used to evaluate signiﬁcant differences
ssociation of IL-1RA Mspa-I 11100 C/T genotype with ID (p < 0.005;
R 0.375; CI: from 0.186 to 0.756) was also observed (Table 2).
ender differences in frequency distributions of genotypes were
etected for IL-6 polymorphisms in ID patients. A signiﬁcantly
igher frequency in females than in males was  observed for
L-6 (nt565) G/A SNP (p < 0.05; OR; 2.9011; CI: from 1.1080 to
.5958). In contrast, IL-6 (nt565) G/G SNP was observed more
requently in males than females (p < 0.05; OR; 0.3828; CI: from
.1475 to 0.9932) (Fig. 4). No differences between patients and
ontrols were detected for the other cytokine polymorphisms
xamined.atients and controls. Values are given as percentage of each population. Person’s
 0.001, **p < 0.005 vs control.
4.2. Haplotype analysis of the IL-6 gene
To perform haplotype analysis of the IL6 gene, the genotype
result of −174 was considered, for each individual, together with
the genotype result of nt565 SNPs. All combinations of haplotypes
that were present in patients and controls are shown in Fig. 5. From
this analysis, we  observed that the GG/CA combination was asso-
ciated with a signiﬁcantly increased risk of ID as compared with
the controls (38.1% patients vs 20% controls, p < 0.05; OR: 2.468;
95% CI: from 1.102 to 5.529) and, in contrast, the CA/CA combi-
nation was associated with a minor risk for developing ID (1.3%
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atients vs 14.5% controls, p < 0.05; OR: 0.078; 95% CI: from 0.009
o 0.646) (Table 3). Additionally, in studying the frequency distri-
utions related to gender we detected a statistically signiﬁcant
ifference in the percentage of females who carried the GG/CA
ombination with respect to males (55.2% females vs 44.8% males,
 < 0.05; OR: 2.9; 95% CI: from 1.108 to 7.596) (Fig. 6).able 2
enotype frequencies (%) of cytokines in ID patients and controls.
Polymorphism ID patients
n = a76 [%]
Control subjects
n = a55 [%]
X2 p value
IL-6 [−174]
Genotypes
GG 43 [56.6] 34 [63.0] 0.18 ns
GC  32 [42.1] 12 [22.2] 5.01 0.02
CC  1 [1.30] 9 [16.3] 10.25 0.0017
Alleles
G  118 [77.6]  80 [72.7] 0.83 ns
C  34 [22.4] 30 [27.3] 0.83 ns
IL-6  nt565
Genotypes
GG 46 [60.5] 33 [61.1] 0.01 ns
GA  29 [38.2] 14 [25.9] 2.34 ns
AA  1 [1.3] 8 [14.5] 8.73 0.004
Alleles
G  121 [79.6]  80 [72.7] 1.69 ns
A  31 [20.4] 30 [27.3] 1.69 ns
Polymorphism ID patients
n = b77 [%]
Control subjects
n = b60 [%]
X2 p value
IL-1RAmspa1 11100
Genotypes
CC 6 [7.8] 2 [3.4] 1.22 ns
CT  33 [42.8] 40 [66.6] 7.68 0.009
TT  38 [49.3] 18 [30.0] 5.22 0.02
Alleles
C  45 [29.2%] 44 [36.6] 2.09 ns
T  109 [70.8]  76 [63.4] 1.70 ns
a IL-6 frequencies were not available for 5 patients and 6 controls.
b IL-1RA frequencies were not available for 4 patients and 1 control.
GG/CA GG/GG CA/CA GG/CG GG/GA CG/C A
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IL-6 HaplotypesFig. 5. Graphical representation of IL-6 174 haplotypes in ID patients and controls.
Signiﬁcances were calculated with Person’s chi-square test and Fisher’s exact test.
*p  < 0.05 vs control.
4.3. Serum cytokine levelsTo obtain combined information on serum concentrations of IL-
6 and IL-1RA and their polymorphisms in ID patients to identify
correlations with protein release, we measured serum cytokine lev-
els. Signiﬁcantly higher levels of IL-6 were observed in patients
Table 3
Combinations of IL-6 haplotypes in ID patients and controls.
IL-6 gene
[−174/nt565]
ID patients
n = 76 [%]
Controls
n = 55 [%]
OR [95% CI] p value
GG/CA 29 [38.1] 11 [20] 2.468 [1.102–5.529] 0.03
GG/GG 43 [56.6] 32 [58.2] – ns
CA/CA 1 [1.3] 8 [14.6] 0.078 [0.009–0.646] 0.01
GG/CG 3 [4] 1 [1.8] – ns
GG/GA 0 [0] 2 [3.6] – ns
CG/CA 0 [0] 1 [1.8] – ns
OR, odds ratios.
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ith the −174 GC genotype compared with control subjects
8.75 ± 7.5 pg/ml vs 5.69 ± 3.2 pg/ml, p = 0.004) (Fig. 7). However, no
igniﬁcant difference of IL-1RA serum concentrations was  observed
n ID patients compared with the controls (630.65 ± 92.37 pg/ml vs
39.48 ± 125.78 pg/ml).
. Discussion
Intellectual disability, according to a deﬁnition by the Amer-
can Association on Mental Retardation (AAMR), is characterized
y signiﬁcant limitations of intellectual functioning and adaptive
ehavior, considered as a set of adaptive skills conceptual, social
nd practical. This disability is a condition diagnosed before the
ge of 18. There are many causes of ID, however, speciﬁc causes
re only identiﬁed in 25% of cases and the diagnosis is often not
ade until the child is in elementary school and has difﬁculty in
astering academic skills. The delay in diagnosis is a critical issue
hen planning care, because early intervention programs, includ-
ng appropriate sensory, motor and cognitive activities, may  give
hildren with ID the best chance of success.
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Excluding the syndromic intellectual disability, in which intel-
lectual deﬁcit associated with other medical and behavioral signs
and symptoms are present, the diagnosis of non-syndromic intel-
lectual disability, in which intellectual deﬁcit is the sole clinical
feature, is based only on speciﬁc clinical assessment tools. How-
ever, the distinction between syndromic and non-syndromic ID is
often blurred. A better understanding of the molecular and genetic
causes of ID might help clinicians to perform more accurate diag-
noses when planning therapeutic interventions. Genetic causes of
ID are thought to be present in 25–50% of cases and increasing num-
bers of genes are being identiﬁed that cause ID, although certain
pathways and molecules are emerging as central contributors to
normal cognition.
To the best of our knowledge, this is the ﬁrst study to evaluate
the involvement of cytokines in individuals with ID. We  report a
signiﬁcant association between mild/moderate ID and SNPs of two
main pro-inﬂammatory cytokines. Speciﬁcally, the genotype T/T of
Mspa-I 11100 in IL-1RA and the genotype G/C of (−174) in IL-6
are associated with an increased risk of developing ID. Moreover,
analysis of the possible combinations of haplotypes formed by the
two SNP (−174 and nt565) of IL-6 has shown that the presence of
the GGCA haplotype constitutes a risk factor for ID. We  reported
that the prevalence of mental retardation was  higher among males
than females, in accord with many other previous studies. Surpris-
ingly, we observed a gender difference for IL-6-nt565 genotypes.
This gender divergence remained evident when we analyzed the
IL-6 haplotypes. The G/A 565nt IL-6 genotype was  more frequent
in females, but alone it was  not associated with ID. However, the
GGCA risk haplotype is an unfavorable predisposing genetic factor,
particularly for females. Even if genetic variation among differ-
ent populations accounted for the divergent results, these ﬁndings
show that gender differences should be considered in association
analysis, because many genes have been demonstrated to function
differently in males and females. Furthermore, the genotypes C/C
of (−174) and A/A of 565 in IL-6 and the genotype C/T of Mspa-I
11100 in IL-1RA may  be protective toward ID. When serum levels
of IL-6 and IL-1RA were analyzed, high levels of IL-6 were signiﬁ-
cantly associated with the presence of ID but no differences were
detected for IL-1RA between ID and controls. The SNP-174 G/C of
IL-6 was previously associated with increased IL-6 production [28]
and shown to affect in vitro IL-6 transcription and IL-6 plasma lev-
els [29,30]. Although there have been some divergences among
published studies regarding the association between IL-6 SNPs and
IL-6 serum levels [31], it is reasonable to hypothesize that SNP-174
G/C of IL-6 could be used as a marker for local or systemic IL-6
secretion.
Previous studies demonstrated that the IL-6 (-174) polymor-
phism was associated with ID in cystic periventricular leucomalacia
in preterm infants [32] and that the expression of IL-6 increased
in various neurological disorders such as Alzheimer’s disease or
meningitis [33–35]. IL-6 is a regulator of neurogenesis, which
is important for cognitive function and hippocampal-dependent
learning. The association of IL-6 and learning and memory has been
widely reported [6,35–37]. Speciﬁcally, it seems to have a regula-
tory role on LTP in the hippocampus by limiting memory acquisition
both in vitro and in free-moving rats and is dependent on NMDA
receptor activation [38]. Wei  H. et al. [39] demonstrated impaired
cognitive abilities and deﬁcits in learning in mice with elevated
IL-6 in the brain. Moreover, transgenic mice not expressing IL-6
showed improved cognitive functioning [40]. However, IL-6 deﬁ-
ciency was  also shown to impair recognition memory [41]. This
discrepancy might be explained because the basal level of IL-6 may
inﬂuence some forms of learning and memory but not others. Fur-
thermore, it must be noted that cytokines interact in a network
where the function of one cytokine can be modiﬁed, modulated or
substituted by others [42]. It has been hypothesized that IL-6 has
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n opposite role to IL-1 in synaptic plasticity and LTP maintenance,
y inducing negative feedback and inhibiting the effects of IL-1 on
TP maintenance [6,38] and/or by curtailing synaptic improvement
t neighboring synapses [43].
Here, we also reported an association of the genotype SNP Mspa-
 11100 T/T of IL-1RA with ID and a protective role for C/T SNP.
he IL-1 family is a growing family of cytokines also compris-
ng receptors and receptor antagonists IL-1RA. The IL-1 system is
ightly regulated at multiple levels by diverse mechanisms includ-
ng receptor antagonists. Currently, there is no clear evidence for
 causal relationship between IL-1RA and cognitive function, but
t was reported that IL-1RA acts strongly as an IL-1 antagonist by
inding to IL-1R-1 with an afﬁnity higher than that of IL-1 [44]. It
as also demonstrated that IL-1, and particularly IL-1, plays a dual
ole in hippocampal-dependent learning processes [5,45] and that
ncreases in IL-1RA may  prevent the adverse cognitive effects of
L-1 [46]. In contrast, intracerebral injection of IL-1RA worsened
earning and memory in a variety of animal models [47,48] and,
locking of the IL-1ß receptor by IL-1RA during the LTP process in
he hippocampus, impaired the maintenance of LTP [49,50]. Some
tudies have also explored the polymorphic variations of IL-1RA
51,52] in association with attention deﬁcit hyperactivity disorder,
ut with conﬂicting results.
. Conclusions
Our data support the hypothesis that IL-6 may  play an impor-
ant role in the development of ID. Thus, IL-6 gene SNPs might serve
s novel genetic markers of susceptibility for ID in the Italian pop-
lation. In addition, we demonstrated an association between ID
atient IL-6 SNPs and IL-6 serum levels, where ID patients over-
roduced IL-6. Moreover, the polymorphism MSPA1 11100 T/T
L-1RA was associated with a greater risk of developing ID, but no
hanges of IL-1RA levels were detected in patients when compared
o controls.
In conclusion, our ﬁndings suggest that the IL-6 and IL-1RA
olymorphisms as well as the overexpression of IL-6 might
ave signiﬁcant implications in the pathogenesis of ID. Cytokine
creening of ID patients has the potential to become an important
ool in clinical diagnostic settings. Speciﬁcally, the characteriza-
ion of these polymorphisms will provide insight into ID onset
upporting the use of cytokine genes in multi-gene panel analysis
f ID patients. To identify and understand the genetic etiology of
D allows for the opportunity of prenatal diagnosis, guidance with
isease management, acceptance of the disability, and connection
ith other parents and support groups.
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